Research Article
Hydroxyurea Therapy Mobilises Arachidonic Acid from Inner Cell Membrane Aminophospholipids in Patients with Homozygous Sickle Cell Disease
Table 3
Fatty acid composition of red blood cell choline phosphoglycerides of HU-untreated (
) and treated (
) HbSS patients and HbAA controls (
).
| | Fatty acids | HbSS (untreated) | HbSS (treated) | HbAA (healthy control) |
| | 16:0 (Palmitic acid) | 36.7 ± 1.6 | 36.3 ± 1.7××× | 31.8 ± 2.5+++ | | 18:0 (Stearic acid) | 8.9 ± 0.7*** | 10.3 ± 1.2××× | 13.2 ± 1.0+++ | | 20:0 (Arachidic acid) | 0.1 ± 0.03*** | 0.2 ± 0.1× | 0.1 ± 0.1 | | 22:0 (Behenic acid) | tr. | tr. | tr. | | 24:0 (Lignoceric acid) | 0.04 ± 0.01 | 0.05 ± 0.01 | .04 ± 0.01 | | ∑saturates | 46.0 ± 1.3** | 47.2 ± 0.8×× | 45.2 ± 1.9 |
| | 16:1n-7 (Palmitoleic acid) | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 | | 18:1n-7 (Vaccenic acid) | 1.6 ± 0.2 | 1.7 ± 0.3× | 1.4 ± 0.2+ | | 18:1n-9 (Oleic acid) | 18.3 ± 1.1 | 17.7 ± 1.5××× | 14.2 ± 1.5+++ | | 24:1n-9 (Nervonic acid) | tr. | tr. | tr. | | ∑monoenes | 20.2 ± 1.1 | 19.7 ± 1.6××× | 15.9 ± 1.6+++ |
| | 18:2n-6 (Linoleic acid) | 16.3 ± 1.4 | 15.4 ± 2.6××× | 20.7 ± 2.1+++ | | 18:3n-6 (γ-linolenic acid) | 0.1 ± 0.02*** | 0.1 ± 0.03 | 0.1 ± 0.05 | | 20:2n-6 (Eicosadienoic acid) | 0.5 ± 0.1 | 0.4 ± 0.2 | 0.5 ± 0.1 | | 20:3n-6 (Dihomo-γ-linolenic) | 1.9 ± 0.4 | 1.7 ± 0.2×× | 2.1 ± 0.1 | | 20:4n-6 (Arachidonic acid) | 9.6 ± 0.7 | 9.5 ± 1.1 | 9.4 ± 1.5 | | 22:4n-6 (Adrenic acid) | 0.9 ± 0.2 | 0.9 ± 0.2××× | 0.7 ± 0.1+++ | | 22:5n-6 (Osbond acid) | 0.5 ± 0.1 | 0.5 ± 0.1× | 0.6 ± 0.2+ | | ∑metabolites | 13.6 ± 0.7 | 13.1 ± 1.3 | 13.4 ± 1.7 | | ∑n-6 | 29.9 ± 1.6 | 28.4 ± 1.9××× | 34.1 ± 2.7 |
| | 18:3n-3 (α-Linolenic acid) | tr. | tr. | tr. | | 20:5n-3 (Timnodonic acid) | 0.1 ± 0.02 | 0.1 ± 0.05 | 0.11 ± 0.03 | | 22:5n-3 (Clupanodonic acid) | 0.3 ± 0.06 | 0.3 ± 0.07 | 0.3 ± 0.05 | | 22:6n-3 (Cervonic acid) | 0.7 ± 0.2 | 0.8 ± 0.4 | 1.0 ± 0.2++ | | ∑metabolites | 1.1 ± 0.2 | 1.2 ± 0.4 | 1.3 ± 0.3++ | | ∑n-3 | 1.2 ± 0.2 | 1.2 ± 0.4 | 1.4 ± 0.3+ |
| | N6/N3 | 26.58 ± 5.03 | 24.91 ± 6.78 | 25.65 ± 5.09 |
|
|
tr.: trace.
HU-untreated versus treated HbSS patients, *, **, ***.
HU-untreated HbSS patients versus HbAA healthy controls, +, ++, +++.
HU-treated HbSS patients versus HbAA healthy controls, ×, ××, ×××.
|
